Bacil Pharma Ltd Board Meeting Scheduled to Approve Rights Issue of Up To ₹50 Crores
Bacil Pharma Ltd has scheduled a meeting of its Board of Directors to consider and approve a proposal for raising funds through a rights issue of equity shares. The meeting is set for Thursday, July 9, 2026.The primary objective of the proposed rights issue is to raise an aggregate amount of up to ₹50,00,00,000 (Rupees Fifty Crores Only). The board will be required to determine and approve various terms and conditions related to the issuance. These details include, but are not limited to, the issue size, the rights entitlement ratio, the issue price, the record date, and the overall rights issue schedule.
The agenda for the meeting includes several critical corporate actions necessary to facilitate this fundraising effort. In addition to finalizing the terms of the Rights Issue, the board must consider a proposal to increase the Authorised Share Capital of the Company if required. This capital increase would ensure adequate capacity for the planned issuance of equity shares. Furthermore, the meeting will address the consequent alteration of the Capital Clause of the Memorandum of Association and any related documents.
The Board agenda also includes discussions on the Appointment and Resignation of Directors, along with any other matters connected to the proposed Rights Issue and the increase in Authorised Share Capital.
In a related operational update, the company has specified that the Trading Window for dealing in the securities of Bacil Pharma Ltd shall remain closed for all designated persons and their immediate relatives until 48 hours following the declaration of the outcome of the Board Meeting.
Stock Price Movement
Bacil Pharma Ltd settled at ₹39.85 on Friday, dipping 0.65% as the stock closed for the day. The shares experienced an intraday range, testing highs near ₹40.11 before finding support down to ₹38.31.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.